Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy
Sanofi SA (NASDAQ:SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast…
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer
Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former’s SRF388, anti-IL-27 antibody, in combination…
Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab…
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 3)
Nanobiotix’s Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
Nanobiotix (NASDAQ:NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that…
Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution
Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations…
AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating…
Merck’s Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting
Merck & Co (NYSE:MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment…
Albireo Pharma Highlights Presentation Of Data From Phase 3 PEDFIC Study
Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today presented clinical data from its Phase 3 PEDFIC 1 study and an interim data cut of the
Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial
Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001…